Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Target of Rapamycin (TOR) Regulates Growth in Response to Nutritional Signals

Amino Acid Regulation of TOR Complex 1.

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling

Nutrient regulation of mTORC1 at a glance

Nutrient sensing and TOR signaling in yeast and mammals

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

mTOR Signaling in Growth Control and Disease

Target of Rapamycin in Control of Autophagy: Puppet Master and Signal Integrator

The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease

TOR Complexes and the Maintenance of Cellular Homeostasis

TOR in plants: Multidimensional regulators of plant growth and signaling pathways

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Regulation of mTORC1 by Upstream Stimuli

mTOR and autophagy: A dynamic relationship governed by nutrients and energy

mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

Phosphoproteomic responses of TORC1 target kinases reveal discrete and convergent mechanisms that orchestrate the quiescence program in yeast